Physician
NPI deactivated
Children's Pediatricians & Associates, LLC
Children's Pediatricians & Associates, LLC was paid $17.46M by Medicaid between Jan 2018 and Dec 2024, across 91 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 25% of everything it billed.
33Billing provider infoCHILDREN'S PEDIATRICIANS & ASSOCIATES, LLC
SILVER SPRING, MD 20904
SILVER SPRING, MD 20904
33aNPI1396932687assigned 10/01/2007
33bProvider typePediatrics Physician
28Total paid$17.46M
24GClaims630,974
24DCodes billed91
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Maryland
Rank by total paid#3 of 306
Median peer was paid$206K
This provider vs. median85×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,334 | $514K | |
| 2019 | 14,016 | $474K | |
| 2020 | 107,295 | $3.33M | |
| 2021 | 181,392 | $3.11M | |
| 2022 | 142,467 | $4.48M | |
| 2023 | 101,975 | $3.08M | |
| 2024incomplete | 70,495 | $2.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 25% | 48,775 | 38,927 | $4.43M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24% | 66,248 | 53,372 | $4.25M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 12% | 25,492 | 21,296 | $2.08M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 9.2% | 19,118 | 16,228 | $1.60M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 8.5% | 20,014 | 16,168 | $1.48M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.6% | 8,834 | 7,547 | $804K |
| 99070 | 2.5% | 105,018 | 85,173 | $429K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.9% | 3,016 | 2,579 | $333K |
| 92551 | 1.9% | 37,520 | 31,694 | $329K | |
| 90686 | 1.6% | 21,723 | 16,787 | $280K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.3% | 14,649 | 13,838 | $225K |
| 96160 | <1% | 67,132 | 53,672 | $129K |
79 more codes
| 90670 | <1% | 8,930 | $126K | |
| 90698 | <1% | 8,899 | $116K | |
| 90461 | <1% | 5,433 | $110K | |
| 99173 | <1% | 35,598 | $86K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 7,050 | $67K |
| 96127 | <1% | 17,831 | $64K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,027 | $36K |
| 90680 | <1% | 2,153 | $30K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 676 | $25K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,089 | $24K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,557 | $23K |
| 99174 | <1% | 4,202 | $23K | |
| 90633 | <1% | 1,810 | $21K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 423 | $19K |
| 90656 | <1% | 897 | $18K | |
| 90677 | <1% | 707 | $17K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 163 | $17K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,707 | $16K |
| 90688 | <1% | 1,056 | $15K | |
| 0072A | <1% | 489 | $14K | |
| 0071A | <1% | 581 | $14K | |
| 99381 | <1% | 244 | $14K | |
| 83655 | <1% | 1,563 | $14K | |
| 99383 | <1% | 128 | $14K | |
| 99384 | <1% | 112 | $14K | |
| 90744 | <1% | 1,018 | $14K | |
| 90651 | <1% | 1,307 | $13K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 590 | $11K |
| 99051 | <1% | 2,876 | $10K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 100 | $10K |
| 85018 | <1% | 6,085 | $9K | |
| 92552 | <1% | 358 | $9K | |
| 96161 | <1% | 3,852 | $8K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 53 | $8K |
| 90620 | <1% | 183 | $7K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 572 | $6K |
| 90619 | <1% | 297 | $5K | |
| 80061 | Lipid panel | <1% | 687 | $5K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 57 | $4K |
| 90734 | <1% | 540 | $4K | |
| 0002A | <1% | 75 | $2K | |
| 91320 | <1% | 45 | $2K | |
| 90480 | <1% | 168 | $2K | |
| 99382 | <1% | 16 | $2K | |
| 90710 | <1% | 126 | $2K | |
| D0191 | <1% | 58 | $2K | |
| 94760 | <1% | 1,855 | $1K | |
| 0051A | <1% | 24 | $1K | |
| 99072 | <1% | 18,337 | $888.28 | |
| 99188 | <1% | 106 | $869.70 | |
| 36416 | <1% | 11,401 | $793.93 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 6,947 | $676.69 |
| 99000 | <1% | 7,887 | $657.96 | |
| 0001A | <1% | 30 | $642.60 | |
| 90715 | <1% | 109 | $633.31 | |
| 0081A | <1% | 13 | $607.23 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 15 | $497.53 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 35 | $437.35 |
| 85014 | <1% | 181 | $424.20 | |
| 90696 | <1% | 38 | $349.41 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 17 | $239.85 |
| 90474 | <1% | 12 | $141.84 | |
| 90685 | <1% | 12 | $116.44 | |
| 99401 | <1% | 28 | $84.82 | |
| A7016 | Dome and mouthpiece, used with small volume ultrasonic nebulizer | <1% | 18 | $53.25 |
| 99058 | <1% | 19 | $40.00 | |
| 90723 | <1% | 17 | $25.16 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 17 | $12.43 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 17 | $3.94 |
| 91307 | <1% | 1,277 | $0.76 | |
| 90716 | <1% | 25 | $0.25 | |
| 90707 | <1% | 12 | $0.12 | |
| 90648 | <1% | 12 | $0.11 | |
| 91300 | <1% | 263 | $0.01 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 15 | $0.01 |
| 91305 | 0% | 106 | $0.00 | |
| G9920 | Screening performed and negative | 0% | 19,020 | $0.00 |
| G9919 | Screening performed and positive and provision of recommendations | 0% | 147 | $0.00 |
| 91308 | 0% | 35 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJANOWIAK, MARK (DIRECTOR OF BUSINESS OPERATIONS)
Parent organizationCHILDREN'S NATIONAL MEDICAL CENTER